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Mood disorders represent one of society’s most costly and challenging
health burdens. The drug treatments used today were initially discovered
serendipitously in the 1950s. Animal models were then developed based
on the ability of these drugs to alter specific behaviours. These models
have played a major role in the development of the second generation of
antidepressants. However, their use has been heavily criticized, particularly
in relation to whether they recapitulate similar underlying biology to the
psychiatric disorder they are proposed to represent. This article considers
our work in the field of affective bias and the development of a translational
research programme to try to develop and validate better animal models. We
discuss whether the new data that have arisen from these studies support an
alternative perspective on the underlying neurobiological processes that lead
to major depressive disorder (MDD). Specifically, this article will consider
whether a neuropsychological mechanism involving affective biases plays
a causal role in the development of MDD and its associated emotional
and behavioural symptoms. These animal studies also raise the possibility
that neuropsychological mechanisms involving affective biases are a pre-
cursor to, rather than a consequence of, the neurotrophic changes linked
to MDD.
This article is part of a discussion meeting issue ‘Of mice and mental
health: facilitating dialogue between basic and clinical neuroscientists’.1. Introduction
Affective disorders are the most prevalent mental health conditions affecting
modern society, with major depressive disorders (MDD) expected to become
the leading cause of disability adjust life years by 2020. Emotional dysfunction
and symptoms such as depression and anxiety are also highly co-morbid with
other clinical conditions, particularly in chronic illnesses, such as chronic pain,
addiction and neurodegenerative disorders. Other mental health conditions
such as schizophrenia and bipolar disorder include emotional symptoms
where negative affect and blunted emotions occur either as part of the disease
or because of the medications used. Drug-induced anxiety, depression and/or
suicidal ideation and behaviour are also a major challenge for the pharma-
ceutical industry [1]. For example, the cannabinoid1 (CB1) receptor family
and its associated antagonists showed promise as novel treatments for obesity.
However, evidence of increased risk of psychiatric side effects saw the withdra-
wal of rimonabant (a CB1 inverse agonist) shortly after it was licensed [2]. Other
drug classes have also been linked with increased risk of psychiatric symptoms
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immune-mediated treatment for hepatitis C, interferon alpha
[3,4]. This diversity of clinical scenarios further illustrates the
complexity of the problem and the challenges researchers
face when trying to elucidate their cause(s) and develop
effective treatments.
One of the primary challenges for all mental health
conditions is being able to understand the underlying neuro-
biological processes that contribute to the disease. All drugs
currently used in the treatment of psychiatric disorders
were initially discovered because of clinical observations of
novel agents, often being tested for entirely different indi-
cations. The detailed pharmacology of the drugs was not
understood until many years after they were first used
therapeutically [5]. As the field of psychopharmacology
developed, a much better understanding of the individual
receptor targets and biochemical effects of these drugs has
been characterized. A very important outcome of this was
the development of more selective drugs that could achieve
similar biochemical effects but with a reduced side effect
burden and improved safety. The development of the seroto-
nin specific re-uptake inhibitors provides an excellent
example of this. These drugs are now the most widely used
treatments for both anxiety and MDD and are often
prescribed to other patient populations to try to address
co-morbid mood symptoms.
Although significant progress has been made in the
development of better antidepressant drugs in terms of side
effects and safety, knowledge about how their biochemical
effects translate into improvement in mood remains limited.
A major limiting factor has been the relationship between
basic and clinical research. MDD is a disease characterized
by a broad range of symptoms that are largely defined
based on subjective self-report measures (e.g. DSM-V [6]).
These criteria cannot be replicated directly in a pre-clinical
scenario and as such, current animal models are assessed
based on criteria such as face (resembles some characteristic
of the human condition e.g. anhedonia, behavioural despair),
construct (arises as a consequence of similar predisposing fac-
tors e.g. stress, genetic vulnerability, early life adversity) and
predictive validity (the ability to predict in an animal the clini-
cal effects of a treatment) [7–9]. No animal model for MDD
has yet been developed that has achieved all three of these
validation criteria. There is also a problem with poor trans-
lation between animal research and clinical benefits, with
few new pre-clinical drugs being successfully taken forward
to licensing. To try to address this, we have taken a novel
approach building on developments in objective measures
of emotional dysfunction in the clinical and experimental
medicine fields. This article summarizes progress to date and
considers the possible implications of the findings that have
arisen from our validation work and investigations into
novel neurobiology.2. Limitations of current animal models
Previous authors have considered this issue in detail and as
such, this section will only discuss animal models of
depression briefly and in the context of the work presented
here. The discussion also only considers methods used to
test for depression-like behaviours and has not considered
the methods used to induce a depression-like phenotype.For more detailed reviews of animal models used in psychiatry
or depression research see [7,10–19].
Modelling human psychiatric disorders in animals is
always going to present a challenge as researchers try to
align subjective self-report measures of emotional disorders
with a behavioural output in an animal, usually a rodent.
The very nature of the attempts to relate animal to human be-
haviour leads to inevitable anthropomorphisms and the
reality is that it is impossible to prove or disprove whether
these behaviours are analogous. The classic behavioural
tests in rodents are the forced swim test (FST) (rats) and tail
suspension test (TST) (mice). These were originally devel-
oped to test for and predict antidepressant efficacy in the
clinic [20,21]. Validation of these tests came from the ability
of known antidepressant drugs to modify escape behaviour
in animals in a way that was not seen with other psychoactive
compounds (although Porsolt and others have warned of the
potential confounds with locomotor stimulants) [13,22,23].
The tests have been very useful in the development of the
second-generation antidepressants, however, use in phenoty-
pic studies and research into underlying neurobiology are
more controversial. Although the FST/TST have some face
validity in that the animals exhibit behavioural despair in
response to an inescapable stressor, how well this aligns
with human MDD is less clear. In a recent review, Commons
et al. [19] proposes that the FST and TST are measures of
stress coping. Furthermore, the time course of effects has
always been problematic. For example, both conventional
delay-onset antidepressants and the rapid onset antidepress-
ant, ketamine, have effects in the FST/TST following acute
administration, something that is not seen in the clinic.
An alternative approach for assessing a behavioural phe-
notype relevant to depression has been the use of the sucrose
preference test (or in some studies ICSS (intracerebral self-
stimulation threshold) [18,24,25]). These tests are designed
to measure an animal’s hedonic response and to detect the
development of an anhedonic phenotype. It has certainly
been the case that chronic stress leads to a reduction in
sucrose preference and this can be reversed by antidepressant
treatments [26]. However, evidence of this type of hedonic
deficit in patients is less robust. Loss of pleasure in daily
activities is a core diagnostic feature in MDD. However, the
human sweet taste test, which attempts to measure in
humans a form of sucrose preference, failed to find a deficit
in patients [27]. It is not clear whether the form of anhedonia
seen in depressed patients is the same as the consummatory
deficit recorded in animals, or more complex and linked with
reward anticipation and expectation [28]. Recently, studies
into depression-like phenotypes in rodents, particularly
mice, have used the novelty supressed feeding test (NSFT)
[29]. This test takes advantage of the natural aversion of
rodents to novel environments and the suppression in feed-
ing behaviour that this stress response induces. Generally
considered to be more of a test of anxiety-related behaviour,
the NSFT is sensitive to the anxiolytic effects of chronic but
not acute antidepressants [30].
Whatever our concerns about animal models and
depression research, animal studies are an essential part of
fundamental biology and drug development. There remains
a large gap in our knowledge that can only really be investi-
gated using a combination of basic research and clinical
investigations. Patient studies are important but often limited
for practical and ethical reasons. Animal studies provide a
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then feed back into the clinic if the methods used in the ani-
mals have translational validity [9]. Translating between
humans and animals cannot be achieved when the human
measure is made using language-based tasks or self-report
measures. It is also not possible to expect an animal model
to recapitulate symptoms such as suicidal ideation or low
mood. However, there are well characterized neuropsycholo-
gical deficits in MDD that do not depend on self-report
measures [31]. The approach we have taken is to look at the
neuropsychological deficits observed in MDD using compu-
terized test batteries, or other objective methods, and then
develop rodent tasks that we predict will depend on similar
underlying neurobiology..R.Soc.B
373:201700363. Affective biases in major depressive disorder:
a neuropsychological biomarker?
Affective biases describe how emotional states can influence
higher cognitive processes. The term has been most com-
monly used to describe biases in attention and emotional
interpretation but similar biases are also proposed to modu-
late other cognitive domains including learning and
memory and decision-making [31–40]. We have therefore
taken a broad interpretation of the term ‘affective biases’
and suggest that this term is relevant across different cogni-
tive domains where the emotional state of the organism
leads to an altered response [31]. This is important when
we consider the relationship between the human measures
of affective biases and the approaches we have used in our
animal work, particularly given that the emotional stimuli
do not readily translate. In our consideration of affective
biases, we have looked more widely at the deficits reported
in MDD and used this evidence to inform our subsequent
animal work (also see discussion by [41]).
While affective biases are not in themselves necessarily a
pathological process, evidence would suggest that negative
biases are a central feature of MDD. The question now is
whether these biases develop because of the disease or in
themselves contribute to its development and maintenance.
Beck first proposed that a cognitive mechanism involving
negative styles of thinking and interpretation played a critical
role in the development and maintenance of mood disorders
[42,43]. While Beck did not specifically focus on the neuro-
biology or neuropsychology of affective bias, his theories
provide a useful foundation for the current ideas around
affective bias and MDD. We have recently reviewed this
topic [31] and therefore this section will provide only a
brief synopsis with an emphasis on key areas relevant to
the animal work and the development of novel behavioural
tasks of affective bias in rodents.
In MDD, patients and at-risk populations tend to exhibit
negative biases in their processing of emotional information,
including biases in interpretation, memory and recall
[32,34,44–49]. The most commonly reported affective biases
in MDD include a reduced ability to recognize happy faces
and increased sensitivity to negative emotions such as
sadness and fear [35]. Although not involving a computer-
ized testing method, studies looking at autobiographical
memory suggest that negative biases may also affect the
patient’s perception of their environment and relationships
as well as their associated memories [33,48,50,51]. The mostimportant breakthrough in this area in terms of developing
animal models has been the work by Harmer and colleagues
[52–55] (also see this issue). Their work first suggested that
antidepressant drugs could interact with neuropsychological
processes to modify emotional interpretation. Not only did
this link the drugs’ effects with a relevant neuropsychologi-
cal process, but the group also observed these effects
following acute administration, in stark contrast to previous
studies suggesting delayed onset. Healthy volunteers or
patients were shown to respond to acute treatment with
either a noradrenaline re-uptake inhibitor, reboxetine or sero-
tonin specific re-uptake inhibitor, citalopram [52,53]. The
participants did not report any subjective changes in mood,
suggesting that these objective shifts in emotional processing
could occur without conscious awareness [54,55]). The same
group have also shown that emotional memory is similarly
biased by acute antidepressant treatments [54,55]. Overall,
this work suggests that negative biases in cognitive processes
could provide a ‘neuropsychological biomarker’ for MDD.
These biases are sensitive to acute modulation with anti-
depressant treatments that may predict longer term efficacy.
For animal researchers, these tasks also provide a valuable
starting point for developing new models to study
depression-related behaviours.4. The development and validation of rodent
tasks of affective bias
Our research has focused on two different cognitive domains:
learning and memory and decision-making. These cognitive
domains lend themselves more favourably to being studied
in animals and, although not the same as the human tasks
based on emotional stimuli, we suggest that they still
measure behaviours relevant to the wider discussions sur-
rounding affective biases, cognition and MDD. To study
affective biases in relation to learning and memory, we devel-
oped the affective bias test (ABT) [56,57]. This task uses
associative learning between a specific cue and reward to
test the influence of affective state at the time of learning on
the subsequent relative valuation of that reward. This task
is different from reward learning tasks such as probabilistic
learning [58–60] as it looks at the animal’s memory of the
experience, and relative value of the reward attributed to it,
rather than the ability to learn about the current reward
opportunities and adapt their behaviour accordingly. The
judgement bias task (JBT) is designed to test affective
biases linked to decision-making behaviour and tests
animals’ interpretation of ambiguous information within
the context of positive versus negative or less positive associ-
ations. This task was originally designed by animal welfare
researchers to facilitate their objective assessment of affective
state in non-human species [61] but has proved to be a land-
mark study in terms of the wider field of affective biases.
Aspects of the JBT may be like other tasks where animals’
responses to reward and punishment are measured i.e. prob-
abilistic learning tasks [60], however, the primary objective of
the model is not to observe changes in responses to the refer-
ence cues but to see a specific shift in interpretation of an
ambiguous cue. The general strategy we have used from
the design of the task to deliver novel biology is outlined in
figure 1. This is still a work in progress but ultimately may
provide a new platform for novel biology and drug
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Figure 1. Schematic representation of a strategy for the development and validation of novel, translational behavioural methods for translational psychiatry. The
choice of behavioural measure is key and should be specific to the condition of interest, objective and quantifiable. The process of developing the task and validation
is illustrated through to the ideal scenario whereby the resulting behavioural approach can be across species to investigate novel biology, identify and develop new
therapeutics and ultimately, test these in the same behavioural test in both pre-clinical and clinical drug development.
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on the reverse translation back to humans could also help
provide tasks for clinical trials.
Developing tests for affective biases in rodents required a
shift from studies in humans that use emotional stimuli e.g.
faces or words, to cues that were relevant to other species.
Animals lack language and while they may use facial cues
and body language to communicate emotional information,
this is unlikely to provide a realistic task for laboratory
research. The first example was published by Harding et al.
[61] in a study in rats. This task was based on human tasks
that used ambiguous stimuli to probe affective state with evi-
dence that negative mood states were strongly associated
with pessimistic interpretation under ambiguity. The task
involved training animals to associate previously neutral
cues (in this case, auditory tones) with an emotionally
valenced outcome (reward versus avoidance of punishment).
Once the association was learnt, the animal’s interpretation of
ambiguous cues was tested by presenting an intermediate
frequency cue and then looking at the animal’s choice of
response. Their work showed that animals in a putative nega-
tive affective state were less likely to anticipate reward in the
same way that depressed people are more pessimistic. A
more detailed discussion of this and related work is reviewed
by Hales & Robinson [16]. A variety of different versions of
this task have now been used, including high versus low/
no reward, reward versus punishment avoidance and operant
or spatial tasks [62–65]. The work provided the first empiri-
cal evidence that rodents possessed the neuropsychological
capacity to express affective biases, in this case referred to
as a cognitive affective bias. Similar judgement bias tasks
( JBT) have now been tested in a wide range of species
from flies to humans with similar findings (for review see
Hales & Robinson [16]).Our own work with the JBT has focused on pharmaco-
logical and ethological validation [64,65]. We first adapted
the original task to include active choice for both the positive
and negative/less positive outcomes to reduce potential con-
founds associated with motivational changes. Similar tasks
have also reported by Enkel et al. [62] and Rygala’s group
[63,66–68]. We have tested a range of acute pharmacological
treatments in both a high versus low reward version of the
task and a reward versus punishment task with similar
results [63,64]. Unlike the human emotional interpretation
studies, we failed to observe any effects with acute anti-
depressant drug treatments [65]. Drugs that caused either
anxiety or a stress response induced a negative bias, with ani-
mals becoming more pessimistic following treatment
[62,63,65]. One study has reported a positive effect with
acute doses of citalopram and the same study, as well as
our own, found positive biases following treatment with
amphetamine but not cocaine [65,68]. Chronic antidepressant
treatment does induce a positive bias but the effect develops
slowly over time [64,65]. However, ketamine behaves very
differently and we have recently shown that an acute dose
of ketamine but not phencyclidine (PCP) can induce more
optimistic decisions in this task [69]. These findings seem to
suggest that the effects of antidepressant drugs on decision-
making behaviour in this rodent task occur over a timescale
that more closely reflects the subjective self-report outcomes
of treatment as opposed to the objective effects on emotional
processing. The pharmacological data obtained so far do not
show similar effects, or time course of effects, for the anti-
depressants tested, suggesting that decision-making in this
rodent task involves different underlying neurobiology
from the human emotional interpretation tasks. This may
be because the animal task uses learnt associations between
the cue and the affective outcome whereas the human tasks
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Figure 2. Summary of the pharmacological and psychosocial manipulations tested in the validation of the affective bias test (ABT). The results show that changes in
absolute reward value as well as antidepressant drugs and social enrichment induce positive biases following acute treatment. In contrast, risk factors linked to the
development of MDD in humans cause negative biases in this task. Adapted from [56,74,75]. LPS, lipopolysaccharide.
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also be influenced by the prolonged training procedures
required to teach animals the task, which can result in
responding based more on procedural learning. Although
the lack of concurrence with the human literature is disap-
pointing, the differential effects seen for delayed versus
rapid onset antidepressants are interesting and suggest this
task may be useful for predicting the efficacy and time
course of novel antidepressants. We have tried reverse
translation of this rodent task for use in humans [70] and
observed a correlation between anxiety and pessimistic
behaviour in healthy volunteers. However, further studies
using pharmacological treatments and in patients with
depression are needed.
Patients with depression attribute less value to rewarding
experiences than non-depressed people, particularly when
they are considering past experiences [33,48,50,51]. Imaging
studies also suggest blunted responses to rewarding stimuli
and cues predicting reward [71–73]. We hypothesized that
affective biases may modify learning andmemory for reward-
ing experiences and that this could be measured in an animal
task. In the ABT, an animal is given two independent learning
experiences and then asked ‘which do you prefer?’ during a
preference test. The learning we use is the association between
a specific digging substrate (the cue) and a fixed value food
reward (45 mg rodent reward pellet). The pairing sessions
are carried out on different days and involve discrimination
learning, with the animal deemed to have learnt the associ-
ation when it can discriminate between the reward-baited
substrate versus a non-rewarded substrate over six consecutive
correct trials. Each reward association is made on a different
day to ensure independence. This also means that we can
manipulate conditions before one of the learning experiences.
Following two pairing sessions for each condition (over 4 con-
secutive days), the animals are then presented with both of the
previously rewarded substrates during a preference test. The
test is carried out with random reinforcement to maintain
responding but reduce any new learning. The resultingchoice bias score is then calculated to determine if the treat-
ment has induced a positive or negative bias. Thus, the idea
behind the task is that the animal will re-activate its memory
for the reward associated with each substrate and then bias
its responding based on the relative value it attributes to
each experience.
Initial proof of concept for the study design was achieved
by testing whether changing the absolute value of the reward
for each substrate–reward association would result in a posi-
tive bias towards the substrate associated with the higher
value reward (figure 2). Once these proof of concept data
were obtained, we progressed to testing a range of pharmaco-
logical interventions that have either antidepressant or
pro-depressant effects in humans. We also tested the effects
of psychosocial manipulations of affective state and drugs
that have effects on the immune system (figure 2). Manipula-
tions tested that induced a negative bias following acute
treatment have all been linked to causing mood-related
impairments in humans. We also find that antidepressants
from a range of different classes induce a positive bias but
neither drugs of abuse nor the failed antidepressant and neu-
rokinin1 (NK1) antagonist, aprepitant, had a significant effect
[56]. The work published in 2013 also showed that the bias
could be observed irrespective of whether the treatment
was given before or immediately after learning, suggesting
a more complex integration of affective information with
the substrate–reward association. We also observed that the
bias increased with each successive pairing session [57]. We
speculate that this may involve longer term memory consoli-
dation processes. In a more recent series of experiments, we
attempted to link the animals’ performance in the ABT
with neural circuits implicated in MDD, namely the amyg-
dala and medial prefrontal cortex (mPFC). We also used the
ABT to investigate whether the temporal differences in
efficacy observed with delayed versus rapid onset anti-
depressants involved different interactions with this
neuropsychological mechanism. In this study, we observed
that biases linked to new learning were mediated through
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mation of a positive bias to venlafaxine and attenuated
negative biases induced either pharmacologically or through
stress [57]. The rapid onset antidepressant, ketamine, failed to
have any effect on new learning so we tested whether pre-
treatment with ketamine before the preference test could
modify a previously learnt negative bias. We hypothesized
that ketamine may mediate its rapid effects through an ability
to block the negative affective bias associated with a previous
memory. This was found to be the case as ketamine but not
the conventional antidepressant, venlafaxine, was able to
block negative biases induced by pharmacological or
stress manipulations [57]. We were also able to localize
this effect to the mPFC and found that inactivation of
this brain area induced a similar attenuation. Importantly,
this work has linked the ABT to a neural circuit implicated
in MDD. Imaging studies suggest that dysfunctional
activity in both the subgenual cingulate and amygdala
are observed in MDD and studies suggest that remediation
of this dysfunction corresponds with antidepressant effi-
cacy [76]. This circuit may also be the target for deep
brain stimulation [36,77].
Providing robust validation of an animal model for psy-
chiatry research is not straightforward but is critical if the
animal model is going to yield research outcomes with clini-
cal relevance. The current methods used for MDD research
have only limited validation with the evidence that both
the FST and TST can produce false positive and false negative
findings. The time course of effects for delayed versus rapid
onset antidepressants in these tests is also problematic as
both can induce changes in immobility time following acute
treatment, something that is not observed in the clinic. In
our validation work, we have tested a range of pharmacologi-
cal manipulations but also used more ethological methods
such as social stress and social enrichment. Validation of
the ABT is now extensive, including studies in different rat
strains and male and female animals [56,78] and suggests
very good predictive and translational validity. Further
work to develop a human version of the task is needed to
help with understanding whether the task also has face and
construct validity. The studies involving the neural circuit
analysis point in a promising direction and suggest similar
brain regions are involved in modulating these behaviours
in the ABT. However, interpretation biases in humans have
been shown to be sensitive to acute antidepressant treat-
ments, which we and others have not seen in the JBT. This
suggests that these behaviours involve different neuropsy-
chological processes. This may arise from the use of cues
with innate emotional associations for the human tasks
versus cues where the association is first learnt by the rats.
The intermediate cue used for the rat studies is either an
intermediate tone frequency or spatial position, which is
also different from the morphed images most often used for
the emotional interpretation tasks. Given that the response
of animals in the JBT shifts in the predicted direction follow-
ing chronic treatment, we suggest that the JBT may involve
decision-making where the choice of response is influenced
by the learned association between the cue and outcome.
Chronic exposure of the animals to the cues while also receiv-
ing treatment may enable these biases to slowly develop as
the learnt associations are altered and start to influence
decision-making behaviour. This could align with the
Harmer model where the objective changes in emotionalinterpretation do not impact on the subjective experience of
mood until sufficient new learning has occurred under the
influence of the antidepressant treatment [54].
Overall the findings for these two tasks suggest that the
affective state of an animal can lead to biases in cognition
when we look in the domains of learning and memory and
decision-making. The results from the antidepressant studies
have revealed some interesting differences. These may be
specific to the rodent work but could reveal new insights
into how affective states modulate different cognitive
domains with distinct time courses.5. Is there a link between affective biases and
anhedonia in major depressive disorder?
To study affective biases in animals, researchers had to move
away from the more typical emotional processing tasks used
in human research and instead relied on tasks where novel
cues are associated with either rewarding or less reward-
ing/punishing events. The results from the ABT suggest
that memory for rewarding experiences is negatively biased
by factors that pose a risk for the development of MDD
[56]. The JBT data also show that negative affective states in
animals result in a reduced anticipation of reward
[61,62,65]. Reductions in reward sensitivity in depression
models has been observed previously using the sucrose pre-
ference test (SPT) [26], however, results for SPT are not
always consistent. Studies using chronic stress or chronic
corticosterone treatments generally find deficits in SPT that
can be reversed by antidepressants [26,79,80]. In contrast,
pro-depressant drug treatments using interferon alpha, rimo-
nabant as well as early life adversity models have not found
equivalent deficits [81–83]. There have also been attempts to
look at reward learning deficits in rodent tasks designed to
recapitulate methods where reward learning deficits have
been reported for patients with MDD, e.g. probabilistic learn-
ing [60]. However, very little pharmacological or phenotypic
data are currently available for these tasks. As discussed
above, studies in humans also suggest that the anhedonia
in MDD is not related to the ability to experience pleasure
but is more about the anticipation of reward, suggesting a
more complex, cognitive mechanism. We hypothesized that
the effects we observed in the ABT using acute pro-depress-
ant treatments may result in a more sustained deficit in
anticipation of reward if experienced chronically. The high-
versus low-reward version of the ABT that was used in the
initial validation experiments provided a method to test
this idea. As shown in figure 3, we have now tested animals
that have been treated chronically with pharmacological,
environmental and immunological manipulations. In all
these groups, we observe a profound deficit in their ability
to learn and express a reward-induced positive bias. The find-
ings from the same animals tested using the SPT confirm our
hypothesis that this effect is distinct from consummatory
anhedonia. Except for chronic corticosterone treatment,
which has also previously been shown to impair performance
in the SPT, the deficit observed was specific to reward learn-
ing in the ABT. In a separate study published by Neill and
colleagues, similar impairment in reward-induced positive
bias was observed using the ABT in a sub-chronic PCP
schizophrenia model [84]. This model is used to study the
cognitive and emotional impairments in schizophrenia,
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pose that this is due to a different underlying neurobiology
involving learning and memory of reward-associated events
and the ability of the cue associated with reward to re-acti-
vate those memories and motivate behaviours accordingly.
This is an early finding and more studies are needed to
better understand the underlying neurobiology and its
relationship to MDD. It will also be important to better
understand how the findings in this assay compare with
other types of reward learning deficit in MDD. The modified
ABT does, however, appear to be able to detect in animals a
distinct form of reward deficit that may involve neurobiolo-
gical processes relevant to the development of anhedonia
in MDD.6. Could a neuropsychological mechanism
explain the development of major depressive
disorder and the efficacy of delayed versus
rapid onset antidepressants?
One of the most prevalent current theories about the cause of
MDD centres around stress-induced detrimental effects on
brain morphology causing the behavioural and psychological
symptoms of the disease [86–88]. Similarly, the actions of
both conventional and rapid onset antidepressants are pro-
posed to arise through an ability to reverse these
neuroplastic and neurotrophic deficits, which then leads to
the improvement in symptoms [86–88]. An overview of this
neurotrophic hypothesis is shown in figure 4a. It should
also be noted that a recent review by Harmer et al. (2017)
posed a revised model that is not illustrated here [90]. In
their model, the relationship between observations of
emotional processing biases and studies in animals showing
neuroplasticity changes are discussed, although this model
puts neuropsychological and neuroplasticity mechanisms in
parallel [90]. Studies in animals certainly suggest that there
are detrimental stress-induced changes in brain morphology
including reduced neurogenesis and neuronal atrophy
[91,92]. Recently, studies with ketamine point towards anNMDA-mediated disinhibition of glutamate release leading
to activation of a molecular cascade triggering enhanced
brain-derived neurotrophic factor (BDNF) and rapid synapse
formation [93,94]. The animal data certainly show that these
morphological changes are present but it is still not clear
whether they then cause the observed behavioural changes.
There is also a lack of evidence supporting direct causality,
with studies in animals failing to show the development of
a depression-like phenotype when treatments that directly
interfere with neurogenesis or neurotrophic factors such as
BDNF are tested [95]. Clinical evidence is also limited, with
most of the animal work being linked to the finding that hip-
pocampal volume is reduced in patients with MDD [95].
However, early after diagnosis, patients with MDD do not
show changes in hippocampal volume and evidence suggests
that any reduction in volume correlates with the duration of
the disease rather than the severity [96]. Even though the
synaptogenesis induced by ketamine is rapid and can occur
after a few hours, most studies in patients report behavioural
changes almost immediately and suicidal ideation has been
shown to change less than one hour after the infusion.
Could an alternative hypothesis be that behavioural
changes resulting from negative affective biases lead to the
symptoms of MDD? Do the arising maladaptive behavioural
consequences of these negative biases then lead to the mor-
phological changes in the brain? This alternative hypothesis
is illustrated in figure 4b. In this model, risk factors for
MDD such as stress or pro-depressant drugs first cause a
psychological effect, i.e. negative affective biases. Studies by
ourselves and others have shown that animals in putative
negative affective states make pessimistic decisions when
interpreting ambiguous information linked to cues they
have learnt to associate with either positive events or less
positive/punishing events. We have also shown that learning
and memory associated with reward are effectively devalued
by each successive experience the animal encounters in a
negative affective state [57]. In the modified ABT, animals
in chronic negative affective states fail to appropriately
learn reward value (figure 3). These findings predict that
chronicity results in these negative biases having detrimental
effects on cognition and behaviour, which may then cause
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Figure 4. The neurotrophic hypothesis (a) and an alternative affective bias hypothesis (b), which illustrate the different relationship between behavioural symptoms of MDD
and changes in brain morphology. The novel model proposed here reverses the relationship between neuroplasticity and brain atrophy, suggesting these occur because of the
behavioural changes induced by negative affective biases. *See [89] for more detailed discussion of relevant signalling pathways. BDNF, brain-derived neurotrophic factor.
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there is evidence that would support a causal relationship
between behaviour and changes in hippocampal mor-
phology. For example, studies have observed changes in the
volume of the hippocampus of rodents linked to seasonal
differences in social and foraging behaviour [97]. Environ-
mental enrichment in laboratory animals increases
hippocampal volume [98] and an imaging study in London
taxi drivers found evidence of a greater hippocampal
volume, which was linked to spatial learning [99]. These
may not be directly relevant to MDD but they show that an
organism’s behaviour and environment can influence the
morphology of the brain. In MDD, reduced activity and
engagement in rewarding activities and social withdrawal
are all well-established characteristics of the disease. It is
therefore feasible that these maladaptive behaviours arise
from negative affective biases and could in themselves lead
to changes in brain morphology.7. Differences in their interaction with affective
biases could explain the differential effects of
delayed versus rapid onset antidepressants
The actions of antidepressants could be explained by a
neuropsychological mechanism involving modification of
affective biases that then leads to a normalization of behav-
iour and the subsequent reversal of the morphological
changes (figure 4b). Harmer et al., [54] previously discussed
this idea in terms of emotional processing biases and delayed
onset of antidepressants. The animal work suggests that
affective biases influence cognition beyond the processing
of inherently emotional information. We have shown that
conventional antidepressant drugs can enhance the relative
reward value attributed to experiences encountered following
acute treatment, an effect that can increase with each succes-
sive experience. Similarly, conventional antidepressants,
when given chronically, cause a gradual shift towards more
positive/less negative decision-making in animals, an effect
that may be linked to learning and memory. Although not
yet tested empirically, the data for the ABT and the effects
of conventional antidepressants on learning and memory
may directly contribute to the effects seen in the JBT with
chronic treatments. The effects of ketamine are particularlyinteresting in these models since the results for the ABT
suggest that ketamine works through its ability to attenuate
previously learnt negative biases, an effect that we link to
neuronal activity changes in the mPFC as opposed to a
neuroplastic effect [57]. Our results find effects following
only 30 min pre-treatment and are the same for mPFC infu-
sions of ketamine and the GABAA agonist, muscimol. We
also find that ketamine can induce a rapid positive bias in
the JBT that we do not observe with the NMDA antagonist,
PCP, which is also not an antidepressant in people [100]. In
our model, ketamine is only able to modulate negative
biases and we failed to see any effects in the ABT in terms
of new learning [56], which could explain why its effects
are short-term and limited. We hypothesize that ketamine
may be acting to neutralize negative biases, enabling patients
to shift from a negative affective state to a more neutral state
rapidly. This results in a rapid shift in scores in measures of
depression and loss of suicidal ideation but they are not
being shifted to a positive state. In contrast, conventional
antidepressants lack the ability to modify previously
acquired negative biases and are therefore delayed in their
efficacy because new learning is needed to outweigh the
negatively biased memories and develop more positively
biased memories and associated behaviours.8. Conclusion
Affective biases offer a plausible neuropsychological expla-
nation for why the symptoms of MDD develop and why
delayed versus rapid onset antidepressants differ in their
time course of effects. These animal studies suggest that
these mechanisms extend beyond emotional processing
biases and their impact on social functioning as discussed
by Harmer et al. [54,90]. They also suggest that there is
a direct interaction between the neurochemical effects of
these antidepressant treatments and neuropsychological
processes that could be used clinically to enhance
efficacy. For example, increasing patients’ re-engagement in
rewarding activities would be a critical component of conven-
tional antidepressant efficacy and the failure of current
treatments to work in some populations may reflect their
inability to achieve this. Our animal work shows that the
symptoms of depression can develop from many different
biological causes but these appear to converge on similar
rstb.royalsocietypublishing.org
Phil.Trans.R.
9
 on January 22, 2018http://rstb.royalsocietypublishing.org/Downloaded from neuropsychological processes. Further studies in both clinical
populations and animals are now needed to test this hypo-
thesis and better understand the exact details of these
relationships. These studies are critical for the development
of new treatments and for improving our understanding of
how to better use current antidepressants. If neuroplastic
and neurotrophic effects are driven by changes in behaviour
then these processes are not necessarily going to provide
the best drug targets. In terms of both novel neurobiology
and the development of new treatments, the ABT and JBT
provide useful animal tasks with the potential for better
translation to the clinic. It would also be useful to further
develop human tasks that work in similar domains so that
even closer translation between human and animal work
can be achieved.Data accessibility. This article has no additional data.
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